How Substance P Drives Neuropathic Pain Signaling
Peptide Approaches to Neuropathic Pain
11 amino acids
Substance P is an 11-amino-acid neuropeptide released from sensory neurons that amplifies pain signals through NK1 receptor activation in the spinal cord.
Zieglgansberger, Cell Tissue Res, 2019
Zieglgansberger, Cell Tissue Res, 2019
View as imageSubstance P was one of the first neuropeptides ever identified. Isolated in 1931 by Ulf von Euler and John Gaddum from horse brain and intestine, it has spent nearly a century at the center of pain research. The 11-amino-acid peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met) is released from the central terminals of sensory neurons in the spinal cord's dorsal horn, where it binds to the neurokinin-1 (NK1) receptor and amplifies nociceptive signals.[1] In neuropathic pain, the pain that follows nerve damage, substance P's role shifts from a normal signal transducer to a driver of pathological sensitization. For a broader look at peptide-based strategies in this space, see our overview of peptide approaches to neuropathic pain.
The story of substance P in pain is also a story of pharmaceutical failure. NK1 receptor antagonists were developed by nearly every major drug company in the 1990s and early 2000s, and all of them failed in clinical pain trials. Understanding why they failed, and what newer endosomal signaling research has revealed about substance P's mechanism, is essential to understanding where neuropathic pain treatment stands today.
Key Takeaways
- Substance P is released from small-diameter C-fiber and A-delta sensory neurons in the spinal dorsal horn in response to intense or sustained noxious stimuli[1]
- NK1 receptor activation by substance P triggers intracellular signaling cascades (IP3/DAG and cAMP pathways) that sensitize second-order dorsal horn neurons to subsequent input[3]
- In animal models of neuropathic pain, substance P levels increase in the dorsal root ganglia and spinal cord following nerve injury[5]
- Selective destruction of NK1 receptor-expressing spinal neurons in rats eliminated hyperalgesia and allodynia without affecting normal pain reflexes[4]
- Despite strong preclinical evidence, every NK1 receptor antagonist tested in human pain trials failed to produce meaningful analgesia[7]
- Recent research suggests substance P drives sustained pain signaling from within endosomes after NK1 receptor internalization, a mechanism that surface-level antagonists cannot block
What Is Substance P and Where Is It Found?
Substance P belongs to the tachykinin family of neuropeptides, which also includes neurokinin A and neurokinin B. It is encoded by the TAC1 gene (also called preprotachykinin A) and produced primarily in small- and medium-diameter neurons of the dorsal root ganglia (DRG). These are the same neurons responsible for detecting pain, temperature, and itch at the body's periphery.
Once synthesized, substance P is packaged into large dense-core vesicles and transported via fast axonal transport to both the central terminals (in the spinal cord dorsal horn) and the peripheral terminals (in skin, joints, viscera, and other tissues). This dual distribution means substance P acts on both ends of the primary sensory neuron: at the periphery, it promotes neurogenic inflammation; at the spinal cord, it amplifies pain transmission.[1]
The NK1 receptor, substance P's preferred target, is a seven-transmembrane G protein-coupled receptor expressed on second-order neurons in lamina I of the dorsal horn. It is also found on endothelial cells, immune cells, astrocytes, and microglia, giving substance P a remarkably broad signaling profile that extends well beyond simple pain transmission.[2]
How Substance P Triggers Pain at the Spinal Level
Under normal conditions, brief noxious stimuli (a pinprick, a burn) are transmitted primarily by glutamate, the fast excitatory neurotransmitter released from primary afferent terminals in the dorsal horn. Substance P plays a minor role in acute pain. It is released only when stimuli are intense, prolonged, or repetitive, conditions that drive sufficient calcium influx into C-fiber terminals to trigger large dense-core vesicle exocytosis.
When substance P binds the NK1 receptor on dorsal horn neurons, it initiates slow, long-lasting excitatory postsynaptic potentials that outlast glutamate's fast signals by seconds to minutes. The intracellular cascade proceeds through phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which release calcium from intracellular stores and activate protein kinase C (PKC).[3]
PKC phosphorylation of NMDA receptors is the critical bridge between substance P signaling and central sensitization. Phosphorylated NMDA receptors remove their magnesium block at resting membrane potential, allowing them to respond to glutamate under conditions that would normally keep them silent. This transforms second-order dorsal horn neurons from faithful reporters of peripheral input into amplifiers that respond to subthreshold stimuli. The clinical result: allodynia (pain from normally innocuous touch) and hyperalgesia (exaggerated pain from mildly noxious stimuli).[3]
This mechanism means substance P does not cause pain directly. It sets the stage for other signals to be perceived as painful. The peptide is a gain control knob, not a pain signal itself.
Central Sensitization: When Pain Becomes Self-Sustaining
In neuropathic pain following nerve injury, substance P contributes to a state where the spinal cord's pain processing circuitry becomes permanently altered. This is central sensitization: a condition where the central nervous system amplifies sensory input regardless of whether peripheral damage persists.
A 2026 study on the substance P/NK1 receptor system in central sensitization found that sustained NK1 receptor activation alters gene expression in dorsal horn neurons, upregulating pain-facilitating receptors and ion channels while downregulating inhibitory pathways.[9] This transcriptional reprogramming means the nervous system's pain volume control gets turned up and stays up, even after the initial injury heals.
Substance P also activates spinal glial cells. Microglia and astrocytes in the dorsal horn express NK1 receptors, and their activation by substance P triggers release of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6) and brain-derived neurotrophic factor (BDNF). These glial mediators further sensitize dorsal horn neurons, creating a self-reinforcing loop: nerve injury releases substance P, which activates glia, which release mediators that sensitize neurons, which respond to more substance P with greater excitation.[3]
A 2019 review by Zieglgansberger detailed how this loop contributes to pain chronicity, the transition from acute pain following injury to chronic pain that persists for months or years.[1] The review argued that substance P's role in this transition makes it qualitatively different from other pain mediators: it does not simply signal damage, it rewires the system.
The Peripheral Role of Substance P in Nerve Injury
Substance P's effects on neuropathic pain are not limited to the spinal cord. At peripheral nerve injury sites, substance P is released from the damaged ends of sensory fibers, where it drives neurogenic inflammation. This involves vasodilation, plasma extravasation (leakage of proteins from blood vessels), and recruitment of immune cells including mast cells, macrophages, and neutrophils.
Peripheral substance P and NK1 receptors contribute directly to inflammatory and neuropathic orofacial pain models. Teodoro and colleagues (2013) demonstrated that NK1 receptor antagonists applied peripherally could reduce both inflammatory and neuropathic pain behaviors in rats, establishing that peripheral substance P signaling represents an independent pain pathway, not just a spillover effect from central release.[5]
In nerve injury models, dorsal root ganglion neurons upregulate substance P production. This upregulation occurs in neurons that do not normally produce substance P, expanding the population of fibers capable of releasing it. The result is a broader, more intense substance P signal reaching both the periphery and the spinal cord from injured nerves.[6]
The relationship between substance P and CGRP (calcitonin gene-related peptide) is relevant here. Both peptides are co-stored and co-released from many of the same sensory neurons. CGRP potentiates substance P's effects on vasodilation and may enhance its pain-facilitating actions at the spinal level. Their combined action is greater than either peptide alone, which partly explains why blocking just one pathway has proven insufficient.
Why NK1 Receptor Antagonists Failed as Painkillers
The strongest preclinical evidence for substance P's role in neuropathic pain came from a 2017 study by Iadarola and colleagues, who used a bioengineered substance P-saporin conjugate to selectively destroy NK1 receptor-expressing neurons in the spinal cord of rats. The result was elimination of hyperalgesia and allodynia in neuropathic pain models, without affecting the animals' ability to detect normal noxious stimuli.[4] This suggested that NK1-expressing neurons are specifically required for pathological pain amplification.
Based on decades of preclinical data like this, pharmaceutical companies developed multiple NK1 receptor antagonists for pain: aprepitant, MK-869, L-758,298, CP-99,994, and others. Every single one failed in human clinical trials for pain. They reduced substance P signaling, confirmed by receptor occupancy studies, but patients reported no meaningful pain relief.[7]
Several explanations have been proposed for this failure. First, rodent and human pain circuitry may differ in NK1 receptor density and distribution. Second, compensatory signaling through neurokinin A (acting on NK2 receptors) and other tachykinins may bypass NK1 blockade. Third, substance P's redundant co-transmission with glutamate means that blocking substance P alone leaves the primary excitatory signal intact.
A 2024 study added a surprising finding: mice genetically engineered to lack both substance P and CGRP-alpha still displayed largely intact pain responses, including chronic inflammatory and neuropathic pain.[8] This directly challenged the assumption that these peptides are required for chronic pain states, suggesting that the nervous system can reroute pain processing through alternative pathways when these peptides are absent from birth. The finding does not negate substance P's role in normal pain processing, but it demonstrates that pain circuitry is far more redundant than single-target drug development assumed. For comparison, endogenous opioid peptides represent the opposite side of this system, suppressing rather than amplifying pain signals.
The Endosomal Signaling Discovery
The most important recent advance in substance P pain research is the discovery that NK1 receptor signaling does not stop at the cell surface. When substance P binds the NK1 receptor, the receptor-ligand complex is internalized into endosomes, membrane-bound compartments inside the cell. From within these endosomes, the NK1 receptor continues to signal for extended periods, generating sustained intracellular calcium release and ERK phosphorylation that outlasts the initial surface binding event.
A 2023 PNAS study demonstrated that endosomal NK1 receptor signaling is the primary driver of sustained pain signaling in the spinal cord, not surface receptor activation. The researchers developed an NK1 receptor antagonist specifically designed to penetrate endosomes, and this endosome-targeted compound produced sustained pain relief in animal models, in contrast to conventional surface-acting NK1 antagonists that failed.
This discovery reframes the NK1 antagonist failure: the drugs worked at the receptor level, but they only blocked signaling at the cell surface. By the time they reached therapeutic concentrations, substance P had already been internalized with the receptor into endosomes, where it continued signaling beyond the drugs' reach. The implication is that the next generation of NK1-targeted pain drugs will need to access endosomal compartments to be effective.
Substance P Beyond Pain: Neuroinflammation and Immune Activation
Substance P's role in neuropathic pain extends beyond direct neural signaling. The peptide is a potent activator of neuroinflammation, a process where immune and glial cells in the nervous system amplify pathological pain states.
In the dorsal horn, substance P activates microglia through NK1 receptors, triggering their transformation from a resting surveillance state to an activated pro-inflammatory phenotype. Activated microglia release a cascade of inflammatory mediators that sensitize surrounding neurons.[3] Substance P also degranulates mast cells at peripheral nerve injury sites, releasing histamine, serotonin, and proteases that contribute to the inflammatory soup surrounding damaged nerves.
Chang and colleagues (2019) mapped the ion channels involved in substance P-mediated nociception, identifying TRPV1, TRPA1, and voltage-gated sodium channels as downstream effectors of NK1 receptor activation.[6] This work revealed that substance P does not simply transmit a single signal; it modulates an entire network of ion channels that collectively determine neuronal excitability.
The overlap between substance P signaling and immune activation has led to interest in NK1 receptor modulation for conditions beyond pain, including depression, nausea (aprepitant is approved as an antiemetic, not an analgesic), and inflammatory diseases. For researchers exploring venom peptides for nerve pain, the ion channel network modulated by substance P provides a map of potential therapeutic targets.
The Bottom Line
Substance P amplifies neuropathic pain through NK1 receptor activation in the spinal dorsal horn, driving central sensitization by unblocking NMDA receptors and activating glial cells. Despite strong preclinical evidence, NK1 receptor antagonists failed in clinical pain trials, likely because they blocked only surface signaling while substance P continued signaling from within endosomes. The discovery of endosomal NK1 signaling has opened a new avenue for pain drug development, though the redundancy of pain circuitry means substance P is one of multiple targets needed for effective treatment.